Marstacimab

Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia[1][2].

Product Specifications

CAS Number

[1985638-39-8]

Product Name Alternative

PF-06741086

UNSPSC

12352203

Target

Thrombin; Tissue Factor Pathway Inhibitor (TFPI)

Type

Inhibitory Antibodies

Related Pathways

Cytoskeleton; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/marstacimab.html

Purity

96.27

Solubility

10 mM in DMSO

Smiles

[Marstacimab]

Molecular Weight

(145.98 kDa)

References & Citations

[1]Patel-Hett S, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019 Sep;25 (5) :797-806.|[2]Pittman DD, et al. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022 Mar 16;6 (2) :e12679.